ONCIN — Oncoinvent ASA Share News
0.000.00%
Last trade - 00:00- NOK305.43m
- NOK200.69m
- NOK28.07m
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee
Brief: Bergenbio Expets Completion Of Merger With Oncoinvent On October 29
Brief: Bergenbio H1 Operating Loss NOK 54.6 Mln
Brief: Oncoinvent EGM Approves Merger Plan With Bergenbio
Brief: BerGenBio and Oncoinvent Announce Proposed Merger and Fully Underwritten Rights Issue to Advance Cancer Therapies
Brief: Bergenbio And Oncoinvent Announce Proposed Merger And Fully Underwritten Rights Issue
Brief: Bergenbio ASA Says Board Considering Sale, Merger, Or Other Strategic Deal
Brief: Bergenbio Mulls Potential Acquisition, Merger, Sale Of Assets
Brief: Bergenbio Q4 Operating Loss NOK 33.5 Mln
Brief: Bergenbio Announces Discontinuation Of 1L Stk11m Nsclc Study And Exploration Of Strategic Alternatives
Brief: Bergenbio Says Appoints Olav Hellebø As CEO
Brief: Bergenbio Q3 Operating Loss NOK 27.2 Mln
Brief: BerGenBio Says CEO Martin Olin Steps Down
Brief: Bergenbio Announces Safety Data From Dose Escalation Phase 1B In First Line NSCLC Patients
Brief: Bergenbio Q2 Operating Loss Widens To NOK 50.8 Mln
Brief: Bergenbio ASA Reports Financial Position Of NOK 200.1 Mln End Of Q2 2024